Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EBV-induced Lymphomas
Conditions
EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Trial Timeline
Mar 1, 1995 → Jul 1, 2019
NCT ID
NCT00002663About Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) is a phase 1/2 stage product being developed by Atara Biotherapeutics for EBV-induced Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT00002663. Target conditions include EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma.
Hype Score Breakdown
Clinical
9
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002663 | Phase 1/2 | Completed |
Competing Products
1 competing product in EBV-induced Lymphomas
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EBV-specific T cells (EBV-CTLs) | Atara Biotherapeutics | Phase 2 | 25 |